The Fritsma Factor newsletter appeared in my in-box today. Loads of useful snippets… the whole anti-phospholipid thing is something of a mystery to me; getting articles on it is always useful. Even if it goes over my head in places.
This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England. One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
2 June 2023 (Friday) - Eltrombopag
A blood
film I was looking at today had the diagnosis “eltrombopag”. Well… I won’t
lile. That meant nothing to me. But Wikipedia came to the rescue.
Eltrombopag
is a medication used to treat thrombocytopenia and severe aplastic anemia. It
is a thrombopoietin receptor agonist.
“Agonist”?
Do they mean “Antagonist”? Apparently (according to Google) “An
agonist is a drug that binds to the receptor, producing a similar response to
the intended chemical and receptor. Whereas an antagonist is a drug that binds
to the receptor either on the primary site, or on another site, which all
together stops the receptor from producing a response”.
I’ve
learned something here…
Subscribe to:
Posts (Atom)